Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01. Notice of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed on July 18, 2025, Neuphoria Therapeutics Inc. (the "Company") received a deficiency notification letter (the "Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the "Listing Rule") as a result of the Company's failure to hold an annual general meeting of stockholders within twelve months of the end of the Company's fiscal year ended June 30, 2024. The Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after the end of the company's fiscal year end. Pursuant to and in response to that Notice, the Company timely submitted its plan to Nasdaq to regain compliance with the Listing Rule (the "Plan").

In response to the Company's Plan, on September 10, 2025, Nasdaq provided the Company further notice that is has accepted our Plan and granted the Company an extension of 180 calendar days (the "Compliance Period") from the end of the Company's fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule.

To this end, the Company intends to file its annual report on Form 10-K on or before September 29, 2025, and thereafter, the Company intends to timely file a proxy statement and notice of shareholder meeting related to the Company's 2025 annual general shareholder meeting, and further intends to hold such annual shareholder meeting within the Compliance Period.